Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.50 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13136612 | 0.91 | RET (0.47) | DGAT1SOAT1KCNH2RETDRD4 | |
| SCHEMBL27728208 | 0.90 | DRD4 (0.55) | DRD4GRM2TLR7SMN1; SMN2HPGD | |
| SCHEMBL1744121 | 0.88 | DGAT1 (0.48) | DGAT1SOAT1KCNH2DRD4GRM2 | |
| SCHEMBL1742250 | 0.86 | DGAT1 (0.53) | DGAT1SOAT1KCNH2RETDRD4 | |
| SCHEMBL13136653 | 0.85 | SLC6A4 (0.46) | DGAT1SOAT1KCNH2RETDRD4 | |
| SCHEMBL12168054 | 0.85 | DGAT1 (0.51) | DGAT1SOAT1KCNH2DRD4GRM2 | |
| SCHEMBL12159841 | 0.84 | DGAT1 (0.50) | DGAT1SOAT1KCNH2RETDRD4 | |
| SCHEMBL1742757 | 0.83 | DRD3 (0.50) | DGAT1SOAT1KCNH2RETDRD4 | |
| SCHEMBL1742748 | 0.82 | DRD3 (0.52) | DGAT1SOAT1KCNH2DRD4GRM2 | |
| SCHEMBL13177715 | 0.81 | DGAT1 (0.48) | DGAT1SOAT1KCNH2DRD4GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | DGAT1 4659/4885SOAT1 2759/4885KCNH2 2830/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | DGAT1 4659/4885SOAT1 2759/4885KCNH2 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.